PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Show more
Location: 18 Hasivim Street, Petah Tikva, 4959376, Israel | Website: https://www.polypid.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
54.37M
52 Wk Range
$2.30 - $3.93
Previous Close
$3.42
Open
$3.42
Volume
39,516
Day Range
$3.36 - $3.50
Enterprise Value
32.95M
Cash
29.46M
Avg Qtr Burn
-6.545M
Insider Ownership
16.70%
Institutional Own.
34.45%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
D-PLEX-100 Details Surgical site infection | NDA Submission |